Citigroup Inc. purchased a new position in Revvity, Inc. (NYSE:RVTY – Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 50,121 shares of the company’s stock, valued at approximately $5,548,000.
Several other hedge funds have also recently added to or reduced their stakes in the business. Public Sector Pension Investment Board acquired a new stake in shares of Revvity during the 3rd quarter valued at $1,472,000. 2Xideas AG acquired a new stake in shares of Revvity during the 3rd quarter valued at $20,968,000. Finally, KBC Group NV bought a new position in shares of Revvity during the 3rd quarter valued at $25,301,000. Institutional investors and hedge funds own 82.63% of the company’s stock.
Insider Buying and Selling at Revvity
In other news, insider Prahlad R. Singh sold 21,217 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $104.28, for a total transaction of $2,212,508.76. Following the sale, the insider now directly owns 92,801 shares of the company’s stock, valued at $9,677,288.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.52% of the company’s stock.
Analyst Ratings Changes
RVTY has been the topic of a number of recent research reports. Wolfe Research initiated coverage on shares of Revvity in a report on Wednesday, December 13th. They set a “peer perform” rating on the stock. Barclays lifted their target price on shares of Revvity from $92.00 to $105.00 and gave the stock an “equal weight” rating in a report on Thursday, January 25th. Stifel Nicolaus lifted their target price on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. KeyCorp lifted their target price on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Finally, Wells Fargo & Company initiated coverage on shares of Revvity in a report on Tuesday, December 19th. They issued an “equal weight” rating and a $95.00 target price on the stock. Six research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $118.91.
Read Our Latest Stock Report on RVTY
Revvity Price Performance
Shares of Revvity stock opened at $104.88 on Friday. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.77 and a current ratio of 2.07. The firm’s 50-day simple moving average is $106.76 and its 200-day simple moving average is $103.11. Revvity, Inc. has a twelve month low of $79.50 and a twelve month high of $139.04. The firm has a market cap of $12.96 billion, a P/E ratio of 19.07, a price-to-earnings-growth ratio of 2.81 and a beta of 1.10.
Revvity (NYSE:RVTY – Get Free Report) last issued its earnings results on Thursday, February 1st. The company reported $1.25 earnings per share for the quarter, beating the consensus estimate of $1.15 by $0.10. The business had revenue of $695.90 million for the quarter. Revvity had a net margin of 25.20% and a return on equity of 7.41%. As a group, research analysts expect that Revvity, Inc. will post 4.65 EPS for the current fiscal year.
Revvity Announces Dividend
The company also recently declared a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Friday, April 19th will be given a $0.07 dividend. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $0.28 dividend on an annualized basis and a yield of 0.27%. Revvity’s dividend payout ratio (DPR) is presently 5.09%.
Revvity Profile
Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.
Featured Stories
Receive News & Ratings for Revvity Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Revvity and related companies with MarketBeat.com’s FREE daily email newsletter.
Source: defenseworld.net
